logo-loader
viewAIM ImmunoTech Inc.

Medsea Estates Group - Annual Report and Accounts

RNS Number : 8661X Medsea Estates Group PLC 30 June 2008 Medsea Estates Group plc (the 'Company') Annual Report and Accounts The report and accounts for the year ended 31 December 2007 have been posted to shareholders today. The report and accounts have been posted on the Company's website (www.medseaestates-ir.com) in accordance with AIM Rule 26 and copies will be available at the Company's registered office, 85 Elsenham Street, London, SW18 5NX. For further information: Medsea Estates Group plc Tony Gatehouse, Chairman Tel: +34 96 570 40 02 Juan Carlos Rodriguez Martinez, Chief Executive HB Corporate Edward Hutton /Imran Ahmad Tel: +44 (0) 20 7510 8600 Media enquiries: Threadneedle Communications Alex White/Josh Royston Tel: +44 (0) 20 7936 9665 This information is provided by RNS The company news service from the London Stock Exchange END ACSBBGDLGDXGGIG

Quick facts: AIM ImmunoTech Inc.

Price: 0.4851

Market: NYSE
Market Cap: $2.35 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

RNS